These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 12719010)

  • 1. Semi-quantitative detection of viral RNA in influenza A virus-infected mice for evaluation of antiviral compounds.
    Sauerbrei A; Ulbricht A; Wutzler P
    Antiviral Res; 2003 Mar; 58(1):81-7. PubMed ID: 12719010
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy of zanamivir against avian influenza A viruses that possess genes encoding H5N1 internal proteins and are pathogenic in mammals.
    Leneva IA; Goloubeva O; Fenton RJ; Tisdale M; Webster RG
    Antimicrob Agents Chemother; 2001 Apr; 45(4):1216-24. PubMed ID: 11257037
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Assessment of development of resistance to antivirals in the ferret model of influenza virus infection.
    Herlocher ML; Truscon R; Fenton R; Klimov A; Elias S; Ohmit SE; Monto AS
    J Infect Dis; 2003 Nov; 188(9):1355-61. PubMed ID: 14593594
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Chemoprophylaxis of influenza A virus infections, with single doses of zanamivir, demonstrates that zanamivir is cleared slowly from the respiratory tract.
    Fenton RJ; Morley PJ; Owens IJ; Gower D; Parry S; Crossman L; Wong T
    Antimicrob Agents Chemother; 1999 Nov; 43(11):2642-7. PubMed ID: 10543741
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of efficacies of RWJ-270201, zanamivir, and oseltamivir against H5N1, H9N2, and other avian influenza viruses.
    Govorkova EA; Leneva IA; Goloubeva OG; Bush K; Webster RG
    Antimicrob Agents Chemother; 2001 Oct; 45(10):2723-32. PubMed ID: 11557461
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of the anti-influenza virus activity of RWJ-270201 with those of oseltamivir and zanamivir.
    Bantia S; Parker CD; Ananth SL; Horn LL; Andries K; Chand P; Kotian PL; Dehghani A; El-Kattan Y; Lin T; Hutchison TL; Montgomery JA; Kellog DL; Babu YS
    Antimicrob Agents Chemother; 2001 Apr; 45(4):1162-7. PubMed ID: 11257030
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Zanamivir Diminishes Lung Damage in Influenza A Virus-infected Mice by Inhibiting Nitric Oxide Production.
    Zablockienė B; Kačergius T; Ambrozaitis A; Žurauskas E; Bratchikov M; Jurgauskienė L; Zablockis R; Gravenstein S
    In Vivo; 2018; 32(3):473-478. PubMed ID: 29695548
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Influenza infection of the embryonated hen's egg/an alternative model for in vivo evaluation of antiviral compounds.
    Härtl A; Sauerbrei A; Stelzner A; Wutzler P
    Arzneimittelforschung; 2004; 54(2):130-4. PubMed ID: 15038464
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dihydropyrancarboxamides related to zanamivir: a new series of inhibitors of influenza virus sialidases. 1. Discovery, synthesis, biological activity, and structure-activity relationships of 4-guanidino- and 4-amino-4H-pyran-6-carboxamides.
    Smith PW; Sollis SL; Howes PD; Cherry PC; Starkey ID; Cobley KN; Weston H; Scicinski J; Merritt A; Whittington A; Wyatt P; Taylor N; Green D; Bethell R; Madar S; Fenton RJ; Morley PJ; Pateman T; Beresford A
    J Med Chem; 1998 Mar; 41(6):787-97. PubMed ID: 9526555
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Synthesis and anti-influenza evaluation of polyvalent sialidase inhibitors bearing 4-guanidino-Neu5Ac2en derivatives.
    Masuda T; Yoshida S; Arai M; Kaneko S; Yamashita M; Honda T
    Chem Pharm Bull (Tokyo); 2003 Dec; 51(12):1386-98. PubMed ID: 14646315
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Highly potent and long-acting trimeric and tetrameric inhibitors of influenza virus neuraminidase.
    Watson KG; Cameron R; Fenton RJ; Gower D; Hamilton S; Jin B; Krippner GY; Luttick A; McConnell D; MacDonald SJ; Mason AM; Nguyen V; Tucker SP; Wu WY
    Bioorg Med Chem Lett; 2004 Mar; 14(6):1589-92. PubMed ID: 15006410
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Development of a novel influenza A antiviral assay.
    Wagaman PC; Leong MA; Simmen KA
    J Virol Methods; 2002 Aug; 105(1):105-14. PubMed ID: 12176147
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dimeric zanamivir conjugates with various linking groups are potent, long-lasting inhibitors of influenza neuraminidase including H5N1 avian influenza.
    Macdonald SJ; Cameron R; Demaine DA; Fenton RJ; Foster G; Gower D; Hamblin JN; Hamilton S; Hart GJ; Hill AP; Inglis GG; Jin B; Jones HT; McConnell DB; McKimm-Breschkin J; Mills G; Nguyen V; Owens IJ; Parry N; Shanahan SE; Smith D; Watson KG; Wu WY; Tucker SP
    J Med Chem; 2005 Apr; 48(8):2964-71. PubMed ID: 15828835
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Virulence may determine the necessary duration and dosage of oseltamivir treatment for highly pathogenic A/Vietnam/1203/04 influenza virus in mice.
    Yen HL; Monto AS; Webster RG; Govorkova EA
    J Infect Dis; 2005 Aug; 192(4):665-72. PubMed ID: 16028136
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of the anti-influenza virus activity of cyclopentane derivatives with oseltamivir and zanamivir in vivo.
    Chand P; Bantia S; Kotian PL; El-Kattan Y; Lin TH; Babu YS
    Bioorg Med Chem; 2005 Jun; 13(12):4071-7. PubMed ID: 15911320
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Synthesis and anti-influenza evaluation of orally active bicyclic ether derivatives related to zanamivir.
    Masuda T; Shibuya S; Arai M; Yoshida S; Tomozawa T; Ohno A; Yamashita M; Honda T
    Bioorg Med Chem Lett; 2003 Feb; 13(4):669-73. PubMed ID: 12639555
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inhibition of influenza virus infections in mice by GS4104, an orally effective influenza virus neuraminidase inhibitor.
    Sidwell RW; Huffman JH; Barnard DL; Bailey KW; Wong MH; Morrison A; Syndergaard T; Kim CU
    Antiviral Res; 1998 Feb; 37(2):107-20. PubMed ID: 9588843
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Characterization of influenza A/HongKong/156/97 (H5N1) virus in a mouse model and protective effect of zanamivir on H5N1 infection in mice.
    Gubareva LV; McCullers JA; Bethell RC; Webster RG
    J Infect Dis; 1998 Dec; 178(6):1592-6. PubMed ID: 9815209
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evidence for zanamivir resistance in an immunocompromised child infected with influenza B virus.
    Gubareva LV; Matrosovich MN; Brenner MK; Bethell RC; Webster RG
    J Infect Dis; 1998 Nov; 178(5):1257-62. PubMed ID: 9780244
    [TBL] [Abstract][Full Text] [Related]  

  • 20. High and continuous exposure of laninamivir, an anti-influenza drug, may work suppressively to generate low-susceptibility mutants in animals.
    Kubo S; Tokumitsu A; Tomozawa T; Kakuta M; Yamashita M
    J Infect Chemother; 2012 Feb; 18(1):69-74. PubMed ID: 21881920
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.